Tag Archive for: AMR

Biocomposites announces two new Phase II clinical trials of STIMULAN VG – a calcium matrix antibiotic carrier mixed with vancomycin and gentamicin – in the U.S.

/in

BLADE-VG2 trial will evaluate the safety and efficacy of STIMULAN VG to treat diabetic foot osteomyelitis BLADE-OPU2 will evaluate the safety and efficacy of STIMULAN VG to treat stage IV pressure ulcers Keele, UK, 7 February 2024 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management […]

Read more

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections

/in

COPENHAGEN, Denmark, Jan. 9, 2024 – The Novo Nordisk Foundation is committing up to USD 25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this […]

Read more

Novo Holdings advances antimicrobial resistance strategy with acquisition of Paratek Pharmaceuticals

/in

Paratek’s successful commercialisation platform to advance novel therapies developed organically and through acquisitions Paratek adds ‘final-mile’ capabilities to AMR efforts COPENHAGEN, September 21, 2023 – With the closing of the acquisition of Paratek Pharmaceuticals, Inc. (“Paratek”), a commercial-stage biopharmaceutical company focused on the development and commercialisation of novel therapies for life-threatening diseases and other public health […]

Read more

Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance

/in

Novo Holdings today announced it has participated in the EUR 30 million Series A Financing of Bactolife. ATHOS led the round, with participation from the Bill & Melinda Gates Foundation, Novo Holdings and other existing investors. Bactolife is a Danish bioindustrial company developing proprietary Binding Proteins™, which strengthen the gut microbiome of humans and animals […]

Read more

Destiny Pharma plc – Positive findings from recent SAB meeting

/in

Confirms proposed Phase 3 development pathway and identifies new life cycle management targets for XF-73 Nasal Brighton, United Kingdom – 6 July 2023 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent life threatening infections, recently held a meeting with its Scientific Advisory Board […]

Read more